Dimopoulos M, Wang M, Maisnar V, et al. Response, progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018, 11(1):49. doi: 10.1186/s13045-018-0583-7.
Advertisement
Articles by Dimopoulos M, Wang M, Maisnar V, et al. Response, progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018, 11(1):49. doi: 10.1186/s13045-018-0583-7.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week
2
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
3
Impact of Automated Insulin Delivery on Type 2 Diabetes Measures
4
Dermatology Practices Absorb Rising Prior Authorization Costs
5